PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CytoDyn Inc. (CYDY)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS23283M1018
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$160.97M
EPS-$0.05
PE Ratio1.51
Gross Profit (TTM)-$20.63M
EBITDA (TTM)-$15.67M
Year Range$0.15 - $0.42
Target Price$4.00

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CytoDyn Inc.

Popular comparisons: CYDY vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in CytoDyn Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%NovemberDecember2024FebruaryMarchApril
-8.77%
17.40%
CYDY (CytoDyn Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

CytoDyn Inc. had a return of -27.00% year-to-date (YTD) and -51.33% in the last 12 months. Over the past 10 years, CytoDyn Inc. had an annualized return of -15.66%, while the S&P 500 had an annualized return of 10.43%, indicating that CytoDyn Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-27.00%5.29%
1 month-14.12%-2.47%
6 months-8.75%16.40%
1 year-51.33%20.88%
5 years (annualized)-20.52%11.60%
10 years (annualized)-15.66%10.43%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-15.00%52.94%-38.46%
2023-9.52%-15.79%6.25%17.65%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of CYDY is 25, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of CYDY is 2525
CytoDyn Inc.(CYDY)
The Sharpe Ratio Rank of CYDY is 3030Sharpe Ratio Rank
The Sortino Ratio Rank of CYDY is 3636Sortino Ratio Rank
The Omega Ratio Rank of CYDY is 3636Omega Ratio Rank
The Calmar Ratio Rank of CYDY is 1919Calmar Ratio Rank
The Martin Ratio Rank of CYDY is 55Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for CytoDyn Inc. (CYDY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


CYDY
Sharpe ratio
The chart of Sharpe ratio for CYDY, currently valued at -0.43, compared to the broader market-2.00-1.000.001.002.003.00-0.43
Sortino ratio
The chart of Sortino ratio for CYDY, currently valued at -0.12, compared to the broader market-4.00-2.000.002.004.00-0.12
Omega ratio
The chart of Omega ratio for CYDY, currently valued at 0.98, compared to the broader market0.501.001.500.98
Calmar ratio
The chart of Calmar ratio for CYDY, currently valued at -0.54, compared to the broader market0.001.002.003.004.005.00-0.54
Martin ratio
The chart of Martin ratio for CYDY, currently valued at -1.58, compared to the broader market0.0010.0020.0030.00-1.58
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.79, compared to the broader market-2.00-1.000.001.002.003.001.79
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.61, compared to the broader market-4.00-2.000.002.004.002.61
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.001.002.003.004.005.001.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current CytoDyn Inc. Sharpe ratio is -0.43. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.43
1.79
CYDY (CytoDyn Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


CytoDyn Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-98.34%
-4.42%
CYDY (CytoDyn Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the CytoDyn Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CytoDyn Inc. was 98.40%, occurring on Apr 15, 2024. The portfolio has not yet recovered.

The current CytoDyn Inc. drawdown is 98.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.4%Jun 30, 2020954Apr 15, 2024
-96.05%Apr 4, 2006216Dec 26, 2007633Apr 28, 2011849
-93.66%Dec 7, 20112003Dec 2, 2019140Jun 23, 20202143
-56.41%May 2, 201183Aug 26, 201170Dec 6, 2011153
-50.91%Nov 23, 200539Feb 2, 200633Mar 22, 200672

Volatility

Volatility Chart

The current CytoDyn Inc. volatility is 20.65%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2024FebruaryMarchApril
20.65%
3.35%
CYDY (CytoDyn Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of CytoDyn Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items